NOS3 (eNOS): The Nitric Oxide Gene That Controls Your Blood Vessel Function
NOS3 encodes endothelial nitric oxide synthase (eNOS) — the enzyme in your blood vessel walls responsible for producing nitric oxide (NO), the molecule that signals smooth muscle to relax and blood vessels to dilate. This single pathway controls your baseline blood pressure, exercise-induced vasodilation, endothelial repair, and cardiovascular aging trajectory.
The most studied variant, Glu298Asp (rs1799983), substitutes glutamic acid for aspartic acid at position 298 of the eNOS protein. This substitution makes the enzyme susceptible to intracellular cleavage, reducing NO bioavailability by up to 30–40%. Approximately 30–40% of most populations carry at least one copy of the Asp298 allele — and most have no idea their blood vessels are working harder than they should be.
What NOS3 Actually Does
Every blood vessel in your body is lined with endothelial cells. These cells express NOS3 (also called eNOS — endothelial nitric oxide synthase), which converts L-arginine into nitric oxide (NO) and L-citrulline. The NO gas diffuses into the smooth muscle cells surrounding the vessel, activating guanylate cyclase, which produces cyclic GMP (cGMP), which causes the muscle to relax. Vessel relaxes → blood pressure drops → tissue gets more oxygen.
This is not optional biology. NO from eNOS is the primary mechanism for:
- ·Blood pressure regulation — Tonic NO release keeps arteries dilated at rest. Reduced NO = chronically elevated vascular resistance = higher blood pressure
- ·Exercise vasodilation — During physical exertion, eNOS activity increases to deliver more blood to working muscles. Impaired eNOS = earlier fatigue, slower recovery, reduced VO2max
- ·Anti-thrombotic protection — NO inhibits platelet aggregation and adhesion. Less NO = blood that clots more easily = increased stroke and heart attack risk
- ·Endothelial repair — NO stimulates endothelial progenitor cells. Without it, the vessel lining accumulates damage faster → accelerated atherosclerosis
- ·Erectile function — Penile erection is fundamentally a NO-mediated vasodilation event. eNOS dysfunction is the primary molecular mechanism behind vascular erectile dysfunction
When NOS3 is functioning normally, your cardiovascular system has a built-in pressure-relief valve that adjusts moment to moment. When NOS3 is impaired, that valve is partially stuck — and every downstream system pays the price.
The Key Variant: Glu298Asp (rs1799983)
NOS3 has several studied polymorphisms, but Glu298Asp (G894T) in exon 7 is the most clinically significant. The ancestral allele encodes glutamic acid (Glu) at position 298; the variant encodes aspartic acid (Asp). This single amino acid change alters the protein's three-dimensional structure, making it susceptible to proteolytic cleavage — the enzyme literally gets cut apart inside the cell before it can produce NO.
Molecular Mechanism
The Asp298 substitution doesn't reduce the enzyme's catalytic activity per se — if you isolate the protein, it works fine. The problem is stability. Inside the cell, the Asp298 variant is preferentially targeted for cleavage, producing 35kDa and 100kDa fragments instead of the functional 135kDa homodimer. The result: fewer intact eNOS molecules → less NO produced per endothelial cell → reduced vasodilation capacity.
This is why the variant is tricky: traditional enzyme activity assays show normal function. The deficit only appears in vivo, where proteolytic processing occurs. It's a stability defect, not a catalytic defect.
Two additional NOS3 variants contribute to overall eNOS function:
- ·T-786C (rs2070744) — Promoter variant that reduces NOS3 gene transcription by ~50%. The C allele means less eNOS mRNA is produced in the first place. Found in linkage disequilibrium with Glu298Asp in some populations.
- ·Intron 4 VNTR (4a/4b) — Variable number tandem repeat in intron 4. The 4a allele (4 repeats instead of 5) is associated with lower circulating NO metabolites and increased CAD risk, particularly in East Asian populations.
Your Genotype: What Each Combination Means
Frequency: ~50% European, ~60% East Asian, ~65% African ancestry
Full-length eNOS protein is stable and produces normal NO levels. Blood vessels dilate efficiently at rest and during exercise. Standard cardiovascular risk from this gene. Responds well to aerobic training with normal blood pressure adaptation.
Clinical impact: Baseline. Standard exercise response. Normal blood pressure regulation. L-arginine and beetroot supplementation still beneficial for performance but not compensatory — enhancement rather than correction.
Frequency: ~38% European, ~30% East Asian, ~28% African ancestry
Approximately half of eNOS protein carries the Asp298 substitution. NO production is reduced by an estimated 15–20% compared to Glu/Glu. Measurable as slightly elevated resting blood pressure (2–3 mmHg systolic) and modestly impaired flow-mediated dilation (FMD) on vascular ultrasound. Most carriers are asymptomatic but accumulate endothelial wear faster over decades.
Clinical impact: 1.2–1.3× increased CAD risk (meta-analyses). Exercise performance slightly below potential — may notice slower warm-up, earlier "pump" fatigue in resistance training. L-citrulline supplementation shows measurable benefit in this group.
Frequency: ~12% European, ~10% East Asian, ~7% African ancestry
All eNOS protein carries the Asp298 substitution. NO bioavailability is reduced by an estimated 30–40%. Resting blood pressure typically 3–5 mmHg higher systolic. Flow-mediated dilation measurably impaired. Endothelial recovery after injury is slower. This genotype represents the highest genetic burden on the NO pathway from this locus alone.
Clinical impact: 1.3–1.9× increased CAD risk depending on population and co-factors. Strongest genetic indication for nitric oxide pathway support through diet and supplementation. Exercise becomes particularly important — regular aerobic training upregulates eNOS expression through shear stress, partially compensating for the protein instability. This is the group where beetroot juice, L-citrulline, and dietary nitrate make the biggest measurable difference.
The Cardiovascular Cascade: How Reduced NO Compounds
NOS3 impairment doesn't just raise blood pressure. It initiates a cascade where each downstream effect amplifies the others:
This is why NOS3 Asp/Asp carriers have a meaningfully higher lifetime cardiovascular risk even when individual measurements (blood pressure, cholesterol) look "borderline normal." The risk isn't from any single parameter being terrible — it's from multiple parameters being slightly worse simultaneously, compounding over 30+ years.
NOS3 and Exercise Performance
Nitric oxide is a master regulator of exercise physiology. During exertion, increased blood flow creates shear stress on endothelial cells, which upregulates eNOS activity in a positive feedback loop: more exercise → more shear → more NO → more blood flow → better performance. NOS3 variants that reduce NO output partially break this loop.
| Performance Domain | GG (Glu/Glu) | GT (Glu/Asp) | TT (Asp/Asp) |
|---|---|---|---|
| VO2max response to training | Normal | Slightly reduced | Measurably reduced |
| Exercise-induced vasodilation | Full | ~85% | ~60–70% |
| Muscle pump / blood flow | Strong | Moderate | Weaker |
| Recovery time | Baseline | +10–15% | +20–30% |
| Altitude adaptation | Normal | Slightly impaired | More susceptible to AMS |
| Elite athlete representation | Overrepresented in endurance sports | Average | Underrepresented in elite endurance |
Studies of elite swimmers and endurance athletes consistently show that the Glu/Glu genotype is overrepresented. A 2019 analysis of Polish elite swimmers found significant enrichment of the GG genotype, particularly in long-distance events where sustained vasodilation determines the ceiling of performance.
The critical nuance: NOS3 genotype affects your ceiling, not yourfloor. Asp/Asp carriers who train consistently will dramatically outperform Glu/Glu carriers who don't — because exercise itself upregulates eNOS expression through shear stress. The genotype determines how much room supplementation and training have to optimize. It never determines whether training works.
Supplement & Dietary Protocols by Genotype
NOS3 is one of the few genes where supplement response is genuinely genotype-dependent. The NO pathway has two distinct input routes — the L-arginine/eNOS pathway (which NOS3 controls) and the dietary nitrate/nitrite pathway (which bypasses eNOS entirely). This matters enormously for supplement selection.
| Supplement | Mechanism | GG Benefit | GT Benefit | TT Benefit |
|---|---|---|---|---|
| L-Citrulline (3–6g/day) | Converts to L-arginine; sustains NO substrate | Moderate | High | HIGHEST — compensatory |
| Beetroot juice / nitrate (400–800mg nitrate) | Nitrate → nitrite → NO (bypasses eNOS) | Moderate | High | CRITICAL — alternative NO pathway |
| L-Arginine (3–6g/day) | Direct eNOS substrate | Mild | Moderate | Limited — enzyme stability is the bottleneck, not substrate |
| BH4 / folate (as 5-MTHF) | eNOS cofactor — prevents uncoupling | Standard | Important | Essential — prevents superoxide generation |
| Vitamin C (500–1000mg/day) | Stabilizes BH4; reduces NO scavenging by ROS | Optional | Helpful | Recommended — protects remaining NO |
| CoQ10 (100–200mg/day) | Reduces endothelial oxidative stress | Optional | Moderate | Recommended — synergistic with NO pathway |
| Omega-3 (2–4g EPA+DHA/day) | Upregulates eNOS expression; anti-inflammatory | Moderate | High | HIGH — genotype-dependent benefit (ARIC study) |
| Grape seed extract (300mg/day) | Endothelial function via polyphenols | Mild | Moderate | Supportive |
The L-Arginine Paradox
L-arginine is the most commonly sold "nitric oxide booster" — and it's the wrong choice for TT carriers. The Asp/Asp genotype has a protein stability problem, not a substrate deficiency. Adding more L-arginine to an unstable enzyme is like putting premium fuel in an engine with broken pistons. L-citrulline is superior because it sustains plasma arginine levels more consistently (better bioavailability, slower release) and avoids the hepatic first-pass metabolism that limits oral L-arginine. And dietary nitrate (beetroot) is the best option because it bypasses the broken eNOS pathway entirely, producing NO through the nitrate → nitrite → NO reduction pathway in the mouth and stomach.
eNOS Uncoupling: When the Fix Becomes the Problem
Under normal conditions, eNOS produces nitric oxide. But when the enzyme loses its essential cofactor tetrahydrobiopterin (BH4), it "uncouples" — instead of producing NO, it generates superoxide (O₂⁻), a reactive oxygen species. This is catastrophic: the enzyme meant to protect blood vessels now actively damages them.
NOS3 Asp298 carriers are more susceptible to eNOS uncoupling because:
- ·The already-reduced NO output means less antioxidant protection for BH4 itself
- ·Oxidative stress from the cardiovascular cascade further depletes BH4
- ·Superoxide generated by uncoupled eNOS reacts with remaining NO to form peroxynitrite (ONOO⁻), which is even more damaging than either alone
This is why BH4 cofactor support is non-negotiable for Asp/Asp carriers. The supplement pathway is: methylfolate (5-MTHF) → supports BH4 synthesis via the folate–BH4 recycling pathway. Vitamin C stabilizes existing BH4 against oxidation. Together they keep eNOS coupled and producing NO instead of superoxide.
The MTHFR connection: If you carry both NOS3 Asp/Asp AND MTHFR C677T (reduced methylfolate production), you have a compound vulnerability: less BH4 cofactor being synthesized AND a less stable enzyme to use it. This double hit makes folate supplementation (as methylfolate, not folic acid) particularly critical. See our MTHFR guide for dosing details.
What NOT to Do
Taking L-arginine alone as your NO booster
For Asp carriers, the bottleneck is enzyme stability, not substrate availability. L-arginine has poor oral bioavailability (first-pass hepatic metabolism absorbs ~40%). L-citrulline is converted to arginine in the kidneys, bypassing the liver, and maintains sustained plasma levels. Always prefer citrulline over arginine — especially if you carry the T allele.
Ignoring the dietary nitrate pathway
Many Asp/Asp carriers try to force-feed a broken eNOS pathway with more substrate. The smarter approach: use the parallel nitrate → nitrite → NO pathway via beetroot juice, arugula, spinach, and celery. This pathway produces NO in the stomach and blood independently of eNOS function. For TT carriers, this isn't a supplement — it's a primary NO source.
Using antiseptic mouthwash before beetroot supplementation
The nitrate → nitrite → NO pathway depends on oral bacteria to convert nitrate to nitrite. Chlorhexidine and other antiseptic mouthwashes kill these bacteria, completely blocking the pathway. Studies show mouthwash use can eliminate beetroot's blood pressure benefits entirely and acutely raise blood pressure by 2–3.5 mmHg. If you're supplementing with dietary nitrate, use fluoride toothpaste instead of antiseptic rinses.
Assuming your blood pressure is 'fine' because it's 125/82
NOS3 Asp/Asp carriers run 3–5 mmHg higher than their genetic potential. A reading of 125/82 might represent 120/78 with proper NO support — the difference between Stage 1 prehypertension and optimal. Track blood pressure over weeks with and without nitrate-rich dietary interventions to find your personal baseline.
Gene Interactions That Modify NOS3 Impact
NOS3 doesn't operate in isolation. Several other genetic variants interact with eNOS function to amplify or buffer the effects of Glu298Asp.
ACE degrades bradykinin, which normally stimulates eNOS to produce NO. The DD genotype (highest ACE activity) destroys bradykinin faster → less eNOS stimulation → less NO. NOS3 Asp/Asp + ACE DD = double hit on vascular relaxation: less stimulation of an already less stable enzyme. This combination carries the highest genetic cardiovascular risk from the vasodilation pathway alone. Consider this the "vascular tension genotype" — the system that should relax your vessels is impaired at two points.
MTHFR converts folic acid to methylfolate, which supports BH4 synthesis — the essential cofactor preventing eNOS uncoupling. MTHFR TT (reduced function) + NOS3 TT = less cofactor for a less stable enzyme. The compound effect: higher risk of eNOS uncoupling, where the enzyme generates superoxide instead of NO. Priority intervention: methylfolate 400–800mcg + vitamin C to maintain BH4 levels.
SOD2 converts superoxide to hydrogen peroxide. The Val/Val genotype (reduced mitochondrial SOD2 import) means more superoxide persists in the cell. Superoxide scavenges nitric oxide, converting it to peroxynitrite. NOS3 Asp/Asp produces less NO + SOD2 Val/Val clears less superoxide = multiplicative reduction in functional NO availability. The intervention is direct: CoQ10 + vitamin C + dietary polyphenols to reduce the superoxide burden that's destroying your remaining NO.
TNF-α directly suppresses eNOS gene expression and promotes eNOS uncoupling via BH4 oxidation. The A allele (higher TNF-α production) + NOS3 Asp/Asp creates a pro-inflammatory, NO-depleted vascular environment. Chronic low-grade inflammation from TNF-α doesn't just cause direct vessel damage — it systematically undermines the NO pathway that would otherwise protect against that damage. Anti-inflammatory protocols (omega-3, curcumin with piperine, exercise) are cardioprotective through this specific mechanism.
PGC-1α drives mitochondrial biogenesis and is a key mediator of exercise-induced vascular adaptation. Carriers of the less active PPARGC1A variant may have a reduced ability to upregulate eNOS expression through exercise-induced signaling. For NOS3 Asp/Asp carriers, this means the training-based compensation pathway (shear stress → eNOS upregulation) may be blunted. Implication: these carriers may need higher training volume to achieve the same vascular adaptation as wildtype for both genes.
COMT Met/Met (slow catecholamine clearance) means higher circulating epinephrine and norepinephrine during stress. These catecholamines cause vasoconstriction — working against the vasodilation that eNOS is trying to produce. NOS3 Asp/Asp + COMT Met/Met = impaired vasodilation under an increased vasoconstriction load during stress. Practical implication: stress management isn't just for mental health — for this genotype combination, it's cardiovascular medicine.
Population Frequencies
| Population | GG (Glu/Glu) | GT (Glu/Asp) | TT (Asp/Asp) | T allele freq |
|---|---|---|---|---|
| European | ~50% | ~38% | ~12% | ~31% |
| East Asian | ~60% | ~30% | ~10% | ~25% |
| African | ~65% | ~28% | ~7% | ~21% |
| South Asian | ~45% | ~40% | ~15% | ~35% |
| Middle Eastern | ~48% | ~38% | ~14% | ~33% |
| Hispanic/Latino | ~55% | ~35% | ~10% | ~28% |
South Asian populations carry the highest Asp allele frequency (~35%), which correlates with the elevated cardiovascular disease burden observed in this population even after controlling for lifestyle factors. The NOS3 genotype distribution is one genetic contributor to the "South Asian cardiovascular paradox" — higher heart disease rates than predicted by traditional risk factors alone.
Lifestyle Protocol for Asp Carriers
Beyond supplementation, several evidence-based lifestyle interventions specifically target eNOS function and NO bioavailability.
Aerobic exercise (150+ min/week)
The single most powerful eNOS upregulator. Shear stress from blood flow mechanically stimulates eNOS transcription via the PI3K/Akt pathway. Regular training can increase eNOS expression by 2–3× regardless of genotype. For Asp/Asp carriers, this partially compensates for protein instability through sheer volume of enzyme production.
Nitrate-rich diet (daily)
Arugula (480mg nitrate/100g), beetroot (250mg/100g), spinach (250mg/100g), celery, radish. These provide NO through the oral bacteria → nitrite → NO pathway, completely independent of eNOS function. This is your parallel NO highway when the eNOS highway has construction.
Dark chocolate (20–40g, >70% cacao, daily)
Epicatechin in cacao directly stimulates eNOS activity and inhibits NADPH oxidase (which generates the superoxide that destroys NO). Multiple RCTs show 2–3 mmHg systolic BP reduction. The effect is additive with exercise and supplementation.
Sauna / heat therapy (3–4×/week)
Repeated heat exposure induces heat shock proteins that stabilize eNOS protein. Finnish sauna studies show significant reductions in cardiovascular mortality with regular use. For Asp/Asp carriers whose core problem is protein stability, heat-induced chaperone upregulation is mechanistically targeted.
Nasal breathing during exercise
Nasal breathing produces NO in the paranasal sinuses (nasal NO). Humming increases nasal NO 15-fold. During exercise, nasal breathing delivers this NO directly to the pulmonary vasculature, improving oxygen exchange. Mouth breathing bypasses this entirely.
Avoid chronic NSAID use
Ibuprofen and similar NSAIDs inhibit eNOS activity and reduce NO-mediated vasodilation. For Asp carriers already running a NO deficit, chronic NSAID use amplifies vascular dysfunction. Use acetaminophen or targeted anti-inflammatory supplements when possible.
Testing and Interpretation
The primary NOS3 variant Glu298Asp (rs1799983) is well covered by consumer genotyping platforms. 23andMe, AncestryDNA, and most direct-to-consumer tests include this SNP. The interpretation is straightforward:
- ·rs1799983 GG → Glu/Glu → Normal eNOS function
- ·rs1799983 GT → Glu/Asp → Heterozygous, mildly reduced function
- ·rs1799983 TT → Asp/Asp → Homozygous, significantly reduced function
For a more complete picture, also check:
- ·rs2070744 (T-786C) — Promoter variant. CC = ~50% reduced transcription. Available on most platforms.
- ·Intron 4 VNTR — 4a/4b repeat. NOT available on SNP chip platforms (requires PCR). Only relevant if clinical testing is done.
Functional validation: If you want to confirm your NOS3 genotype's functional impact, request a flow-mediated dilation (FMD) test from your cardiologist. FMD measures how well your brachial artery dilates in response to increased blood flow — a direct readout of endothelial NO function. FMD <7% is considered impaired and correlates with NOS3 Asp/Asp genotype in most studies.
The Differential Susceptibility Frame
Belsky's differential susceptibility model (2009) applies directly to NOS3. The Asp allele is not simply a "risk allele" — it's a sensitivity allele. Asp carriers are more responsive to both harmful and beneficial environmental inputs:
Harmful Environment
- · Sedentary lifestyle → BP rises more than GG
- · High-sodium diet → greater BP sensitivity
- · Smoking → faster endothelial damage
- · Chronic stress → greater vasoconstriction
- · Poor diet → NO depletion compounds
Supportive Environment
- · Regular exercise → greater BP improvement than GG
- · Nitrate-rich diet → larger NO boost
- · L-citrulline supplementation → bigger effect size
- · Omega-3 intake → more endothelial benefit
- · Sauna use → greater vascular adaptation
This means Asp/Asp carriers have both the highest risk in a bad environment AND the highest return on investment from cardiovascular optimization. The genotype doesn't doom you — it makes your lifestyle choices matter more.
The Bottom Line
NOS3 Glu298Asp is one of the most actionable cardiovascular variants you can test for. Unlike many genetic risk factors where the intervention is "monitor and hope," reduced eNOS function has specific, evidence-based compensations: dietary nitrate bypasses the enzyme entirely, L-citrulline sustains substrate levels, methylfolate prevents uncoupling, and exercise upregulates expression through shear stress.
The Asp/Asp carrier who exercises daily, eats arugula and beetroot, supplements with L-citrulline and methylfolate, and avoids antiseptic mouthwash can achieve NO bioavailability that approaches or matches Glu/Glu carriers who do none of these things. The genotype sets the starting point. The protocol determines the outcome.
Sources & Further Reading
- Casas JP et al. (2006). Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. 164(10):921-935.
- Leeson CP et al. (2002). Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res. 90(11):1153-1158.
- Saunders CJ et al. (2006). No association of the ACTN3 gene R577X polymorphism with endurance performance in Ironman Triathletes. Ann Hum Genet. 70(Pt 6):808-814.
- Ahsan A et al. (2018). Simultaneous selection of the wild-type genotypes of the G894T and 4B/4A polymorphisms of NOS3 associate with high-altitude adaptation. Ann Hum Genet.
- Hobbs DA et al. (2012). Blood pressure-lowering effects of beetroot juice and novel beetroot-enriched bread products in normotensive male subjects. Br J Nutr. 108(11):2066-2074.
- Belsky J et al. (2009). Vulnerability genes or plasticity genes? Mol Psychiatry. 14(8):746-754.
Check Your NOS3 Genotype
Upload your 23andMe or AncestryDNA raw data file and get your personalized NOS3 analysis — including gene interactions with ACE, MTHFR, SOD2, TNF-α, and more.
Analyze Your DNA →